Voriconazole [137234-62-9]
Cat# A4320-200mg
Size : 200mg
Brand : APExBIO Technology
Contact local distributor :
Phone : +1 850 650 7790
Voriconazole is an inhibitor of 14α-lanosterol demethylase with IC50 value of 53nM [1].
Voriconazole is a triazole antifungal and a second-generation synthetic derivative of fluconazole. It plays its antifungal role through inhibiting cytochrome P450 (CYP 450)–dependent 14α-lanosterol demethylation, which is a vital step in the membrane ergosterol synthesis of fungi. Voriconazole has a broad antifungal spectrum. It is active against all Candida species, many Aspergillus species and other yeasts, including Cryptococcus neoformans, Trichosporon beigelii, and Saccharomyces cerevisia. Voriconazole is available in both intravenous and oral formulations. Voriconazole undergoes extensive hepatic metabolism via the cytochrome P450 enzymes, primarily CYP2C9 and CYP3A4. In addition, voriconazole also causes some side effects, such as visual disturbances, skin rashes and elevations in hepatic enzyme levels [1, 2].
References:
[1] Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother. 2000 Sep;34(9):1032-43.
[2] Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003 Mar 1;36(5):630-7.
- 1. Dante G Calise, Sung Chul Park, et al. "An oxylipin signal confers protection against antifungal echinocandins in pathogenic aspergilli." Nat Commun. 2024 May 4;15(1):3770. PMID: 38704366
- 2. Lauriane Blukacz, Sandro Nuciforo, et al. "Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC." Hepatol Commun. 2024 May 2;8(5):e0437. PMID: 38696353
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 349.31 |
| Cas No. | 137234-62-9 |
| Formula | C16H14F3N5O |
| Solubility | ≥34.9 mg/mL in DMSO; insoluble in H2O; ≥45 mg/mL in EtOH with gentle warming and ultrasonic |
| Chemical Name | (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol |
| Canonical SMILES | C[C@H]([C@](C61ncnc1)(c(ccc(F)c1)c1F)O)c(ncnc1)c1F |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
| Cell lines | Aspergillus spp. and Candida spp. |
| Preparation method | The solubility of this compound in DMSO is >17.5mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
| Applications | Voriconazole inhibited Aspergillus spp. and Candida spp. and exhibited excellent activity against Candida spp. with MICs typically <0.125 mg/L. |
| Clinical trial [2]: | |
| Patient models | Aspergillosis |
| Application | In the patients who received primary therapy with voriconazole, 59% had either a complete or a partial response. In the patients who received voriconazole as salvage therapy, 38% had either a complete or a partial response. |
| Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| References: [1] Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother. 2000 Sep;34(9):1032-43. [2] Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003 Mar 1;36(5):630-7. | |
Quality Control & MSDS
- View current batch:
Chemical structure
